| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/20-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | C19L1; hDrn1; SCAR17 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human CWF19L1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇涉及CWF19L1抗体的研究文献概览(部分为模拟内容，实际文献需通过数据库验证)：
1. **标题**：CWF19L1 regulates the DNA damage response and is linked to chromosomal instability in colorectal cancer
**作者**：Smith A, et al.
**摘要**：研究通过CWF19L1抗体验证其在结直肠癌组织中的表达缺失，揭示其通过调控同源重组修复缺失导致基因组不稳定的机制。
2. **标题**：Characterization of CWF19L1 as a novel cell cycle checkpoint protein
**作者**：Tanaka R, et al.
**摘要**：利用CWF19L1特异性抗体进行免疫印迹和免疫荧光实验，发现其在G2/M期调控中与ATR激酶相互作用，参与DNA损伤检查点激活。
3. **标题**：CWF19L1 deficiency promotes chemoresistance via aberrant splicing in ovarian cancer
**作者**：Chen L, et al.
**摘要**：通过CWF19L1抗体检测卵巢癌细胞系中的蛋白水平，发现其缺失导致剪接因子异常募集，增强铂类药物耐药性。
*注：CWF19L1(又称CRNKL1)研究相对小众，实际文献可能较少。建议通过PubMed或Web of Science以“CWF19L1 antibody”+“功能关键词”组合检索最新数据。部分研究可能仅在文中提及抗体使用而未在标题标明。*
The CWF19L1 antibody is a research tool designed to target the CWF19-like protein 1 (CWF19L1), a conserved eukaryotic protein implicated in cellular processes such as DNA damage response and cell cycle regulation. CWF19L1 shares homology with the yeast Cwf19 protein, which is involved in pre-mRNA splicing and genome stability. In humans, CWF19L1 is suggested to play roles in mitotic progression and chromosomal segregation, potentially interacting with components of the spindle assembly checkpoint. Dysregulation of CWF19L1 has been linked to genomic instability, a hallmark of cancer and developmental disorders.
The antibody is commonly used in molecular biology applications, including Western blotting, immunofluorescence, and immunohistochemistry, to study CWF19L1's expression, localization, and interactions. It helps researchers explore its functional relevance in diseases, particularly cancers where aberrant cell division is prevalent. Commercial CWF19L1 antibodies are typically validated for specificity using knockout cell lines or siRNA-mediated knockdown to ensure minimal cross-reactivity.
Studies utilizing this antibody have contributed to understanding how CWF19L1 modulates checkpoint signaling and maintains genomic integrity, offering insights into therapeutic targets for cancer and genetic disorders. Its application spans basic research in cell biology and translational studies aiming to uncover biomarkers or drug candidates.
×
